Univariate analysis of factors potentially associated with grade III-IV aGVHD in 106 DCBT recipients
Variable . | N . | Day 180 grade III-IV aGVHD, % (95% CI) . | P . |
---|---|---|---|
Age, y | |||
0-15 | 14 | 21 (5-46) | .921 |
≥16 | 92 | 21 (13-30) | |
Conditioning | |||
Myeloablative | 80 | 20 (12-29) | .764 |
Nonmyeloablative | 26 | 23 (9-41) | |
Infused total CD3+cell dose | |||
≤7.74 × 106/kg | 55 | 26 (15-38) | .170 |
>7.74 × 106/kg | 51 | 16 (7-27) | |
Dominant unit-recipient 6 allele HLA match | |||
Worse HLA match: 2-3/6 | 28 | 32 (16-50) | .077 |
Better HLA match: 4-6/6 | 78 | 17 (9-26) | |
ST2 level, ng/mL | |||
Low: ≤33.9 | 56 | 13 (5-23) | .024 |
High: >33.9 | 50 | 30% (18-43) |
Variable . | N . | Day 180 grade III-IV aGVHD, % (95% CI) . | P . |
---|---|---|---|
Age, y | |||
0-15 | 14 | 21 (5-46) | .921 |
≥16 | 92 | 21 (13-30) | |
Conditioning | |||
Myeloablative | 80 | 20 (12-29) | .764 |
Nonmyeloablative | 26 | 23 (9-41) | |
Infused total CD3+cell dose | |||
≤7.74 × 106/kg | 55 | 26 (15-38) | .170 |
>7.74 × 106/kg | 51 | 16 (7-27) | |
Dominant unit-recipient 6 allele HLA match | |||
Worse HLA match: 2-3/6 | 28 | 32 (16-50) | .077 |
Better HLA match: 4-6/6 | 78 | 17 (9-26) | |
ST2 level, ng/mL | |||
Low: ≤33.9 | 56 | 13 (5-23) | .024 |
High: >33.9 | 50 | 30% (18-43) |